Furthermore, IL-10 absence enhanced the efficiency of DC-based immunotherapy decreased Treg and MDSC levels in the tumor microenvironment, and boosted Th1-type antitumor responses, indicating that IL-10 promotes tumor growth in CRC [44]. This evidence concerns the gene IL10 and colorectal carcinoma.